Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Operating Leases (2019 - 2025)

Ptc Therapeutics has reported Operating Leases over the past 7 years, most recently at $93.6 million for Q4 2025.

  • Quarterly results put Operating Leases at $93.6 million for Q4 2025, up 24.87% from a year ago — trailing twelve months through Dec 2025 was $93.6 million (up 24.87% YoY), and the annual figure for FY2025 was $93.6 million, up 24.87%.
  • Operating Leases for Q4 2025 was $93.6 million at Ptc Therapeutics, down from $107.3 million in the prior quarter.
  • Over the last five years, Operating Leases for PTCT hit a ceiling of $137.4 million in Q2 2022 and a floor of $71.2 million in Q2 2025.
  • Median Operating Leases over the past 5 years was $93.2 million (2024), compared with a mean of $92.9 million.
  • Biggest five-year swings in Operating Leases: surged 79.72% in 2022 and later dropped 28.8% in 2025.
  • Ptc Therapeutics' Operating Leases stood at $73.6 million in 2021, then surged by 37.0% to $100.9 million in 2022, then dropped by 3.21% to $97.6 million in 2023, then dropped by 23.23% to $74.9 million in 2024, then rose by 24.87% to $93.6 million in 2025.
  • The last three reported values for Operating Leases were $93.6 million (Q4 2025), $107.3 million (Q3 2025), and $71.2 million (Q2 2025) per Business Quant data.